Botulinum toxin type-A treatment in spasticity increases the central conduction time to brain stimulation.
Pauri
F
F
AFaR-CRCCS Centro di Ricovero e Cura a Carattere Scientifico, Divisione di Neurologia, Ospedale Fatebenefratelli, Rome, Italy.
Boffa
L
L
Cassetta
E
E
Pasqualetti
P
P
Rossini
P M
PM
D000200:Action Potentials / Q000187:drug effects; D000328:Adult; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D002490:Central Nervous System / Q000187:drug effects* / Q000503:physiopathology; D019054:Evoked Potentials, Motor / Q000187:drug effects; D005260:Female; D006181:H-Reflex / Q000187:drug effects; D006801:Humans; D008280:Magnetics; D008297:Male; D008875:Middle Aged; D009128:Muscle Spasticity / Q000188:drug therapy*; D009431:Neural Conduction / Q000187:drug effects*; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D010812:Physical Stimulation; D011930:Reaction Time / Q000187:drug effects; D013997:Time Factors
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A